Home › Compare › HAWK vs ABBV

HAWK vs ABBV: Dividend Comparison 2026

HAWK yields 5000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HAWK wins by $1.714033996390774e+30M in total portfolio value
10 years
HAWK
HAWK
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.714033996390774e+30M
Annual income
$1,713,968,144,149,345,700,000,000,000,000,000,000.00
Full HAWK calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — HAWK vs ABBV

📍 HAWK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHAWKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HAWK + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HAWK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HAWK
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,456,872,922,526,944,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, HAWK beats the other by $1,456,872,922,526,944,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HAWK + ABBV for your $10,000?

HAWK: 50%ABBV: 50%
100% ABBV50/50100% HAWK
Portfolio after 10yr
$8.57016998195387e+29M
Annual income
$856,984,072,074,672,800,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HAWK
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HAWK buys
0
ABBV buys
0
No recent congressional trades found for HAWK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHAWKABBV
Forward yield5000.00% ✓3.12%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓40.6%
Portfolio after 10y$1.714033996390774e+30M$104.7K ✓
Annual income after 10y$1,713,968,144,149,345,700,000,000,000,000,000,000.00 ✓$25,725.73
Total dividends collected$1.7140296880110527e+30M$63.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HAWK vs ABBV ($10,000, DRIP)

YearHAWK PortfolioHAWK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,559$438.51+$999.1K → HAWK
2$189,997,337$188,915,887.85$13,494$640.86+$189.98M → HAWK
3$66,583,710,060$66,380,412,909.59$15,951$945.97+$66583.69M → HAWK
4$43,552,957,495,771$43,481,712,926,006.76$19,152$1,413.89+$43552957.48M → HAWK
5$53,208,750,054,973,336$53,162,148,390,452,856.00$23,443$2,146.38+$53208750054.95M → HAWK
6$121,455,664,296,308,770,000$121,398,730,933,749,920,000.00$29,391$3,321.96+$121455664296308.73M → HAWK
7$518,088,597,191,607,700,000,000$517,958,639,630,810,500,000,000.00$37,948$5,265.87+$518088597191607680.00M → HAWK
8$4,130,340,469,031,615,000,000,000,000$4,129,786,114,232,619,600,000,000,000.00$50,795$8,596.74+$4.1303404690316145e+21M → HAWK
9$61,544,150,867,305,510,000,000,000,000,000$61,539,731,403,003,640,000,000,000,000,000.00$71,034$14,549.41+$6.154415086730551e+25M → HAWK
10$1,714,033,996,390,774,000,000,000,000,000,000,000$1,713,968,144,149,345,700,000,000,000,000,000,000.00$104,715$25,725.73+$1.714033996390774e+30M → HAWK

HAWK vs ABBV: Complete Analysis 2026

HAWK — Stock

HAWK is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in HAWK shares.

Full HAWK Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HAWK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HAWK vs SCHDHAWK vs JEPIHAWK vs OHAWK vs KOHAWK vs MAINHAWK vs JNJHAWK vs MRKHAWK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.